Abstract | AIMS: METHODS AND RESULTS: We used IHC to detect MTAP in a cohort of 99 MPMs and 39 reactive mesothelial proliferations (RP) (reactive mesothelial hyperplasia n = 33, reactive pleural fibrosis n = 6). MTAP staining was assessed by an H score. The median H score of the RP cohort was set as a reference point. Cases with H scores below this reference point were considered to have decreased MTAP expression. We found that 64 of 99 (65%) of the investigated MPMs had decreased MTAP expression, while this was only true for nine of 39 (23%) of the RPs (P = 0.001). We further evaluated MTAP expression in a cohort of coagulated pleural effusions from 14 patients with MPM and 20 patients with RP by using a double-staining technique with Wilms tumour 1 (WT1) as a mesothelial marker. In these samples, decreased MTAP expression diagnosed MPM with a sensitivity of 71% and a specificity of 90%. CONCLUSIONS: Decreased MTAP expression could potentially be useful in combination with other markers in the diagnosis of MPM.
|
Authors | Zarah Glad Zimling, Anne Jørgensen, Eric Santoni-Rugiu |
Journal | Histopathology
(Histopathology)
Vol. 60
Issue 6B
Pg. E96-105
(May 2012)
ISSN: 1365-2559 [Electronic] England |
PMID | 22394205
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- Biomarkers, Tumor
- Purine-Nucleoside Phosphorylase
- 5'-methylthioadenosine phosphorylase
|
Topics |
- Biomarkers, Tumor
(metabolism)
- Humans
- Immunohistochemistry
- Mesothelioma
(diagnosis, metabolism, pathology)
- Pleural Neoplasms
(diagnosis, metabolism, pathology)
- Purine-Nucleoside Phosphorylase
(deficiency, genetics, metabolism)
|